Home/Filings/4/0000899243-19-014556
4//SEC Filing

QVT Associates GP LLC 4

Accession 0000899243-19-014556

CIK 0001740547other

Filed

May 22, 8:00 PM ET

Accepted

May 23, 6:26 PM ET

Size

12.9 KB

Accession

0000899243-19-014556

Insider Transaction Report

Form 4
Period: 2019-05-21
Transactions
  • Purchase

    Common Shares, par value $0.000037453 per share

    2019-05-22$8.06/sh+5,033$40,55822,740,305 total(indirect: (see fn6))
  • Purchase

    Common Shares, par value $0.000037453 per share

    2019-05-21$8.52/sh+9,995$85,10822,735,272 total(indirect: (see fn6))
  • Purchase

    Common Shares, par value $0.000037453 per share

    2019-05-23$7.76/sh+4,802$37,25222,745,107 total(indirect: (see fn6))
Transactions
  • Purchase

    Common Shares, par value $0.000037453 per share

    2019-05-22$8.06/sh+5,033$40,55822,740,305 total(indirect: (see fn6))
  • Purchase

    Common Shares, par value $0.000037453 per share

    2019-05-23$7.76/sh+4,802$37,25222,745,107 total(indirect: (see fn6))
  • Purchase

    Common Shares, par value $0.000037453 per share

    2019-05-21$8.52/sh+9,995$85,10822,735,272 total(indirect: (see fn6))
Footnotes (6)
  • [F1]The transaction was a series of open market purchases made in accordance with the safe harbor of Rule 10b-18 ("Rule 10b-18") under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
  • [F2]The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.31 to $8.69, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. ("Urovant"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
  • [F3]The transaction was a series of open market purchases made under a trading plan established pursuant to Rule 10b5-1 under the Exchange Act and in accordance with the safe harbor of Rule 10b-18.
  • [F4]The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.825 to $8.43, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4.
  • [F5]The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.645 to $7.98, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4.
  • [F6]QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,745,107 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.

Issuer

Urovant Sciences Ltd.

CIK 0001740547

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001290166

Filing Metadata

Form type
4
Filed
May 22, 8:00 PM ET
Accepted
May 23, 6:26 PM ET
Size
12.9 KB